Anolinx CEO, Dr. Aaron Kamauu and Colleagues to Present Eight Posters at ISPE Conference

May 20th, 2013 Posted by News No Comment yet

For Immediate Release:
Contact: Greg Hopkins
(888) 968-5469

Salt Lake City, UT – Anolinx, a clinical research and clinical trials recruitment company, announced today that eight abstracts submitted by Anolinx CEO Aaron Kamauu, MD MPH MS, and his colleagues, have been accepted for presentation at the 2013 International Society for Pharmacoepidemiology (ISPE) conference to be held August 25-28 in Montreal, Canada. Dr. Kamauu and his colleagues submitted eight abstracts and all eight were accepted for presentation as posters at the conference. Below is a list of the accepted abstracts with authors.

Using Natural Language Processing to Identify US Veterans with Binge Eating Disorder.
Bellows BK, 1-2 DuVall SL, 1-3 Ginter T, 1,3 Kamauu AWC, 4 Supina D, 5 Hodgkins P, 5 Erder H, 5 LaFleur J. 1-2

  1. VA Salt Lake City Health Care System, Salt Lake City, Utah
  2. University of Utah College of Pharmacy, Salt Lake City, Utah
  3. University of Utah School of Medicine, Salt Lake City, Utah
  4. Anolinx LLC, Salt Lake City, Utah
  5. Shire Development LLC, Wayne, Pennsylvania

Presented: “Poster Session B: SIG Database” on Tuesday, August 27, 2013. The publication number will be 589

Determining Multiple Sclerosis Subtype from Electronic Medical Records.
DuVall SL, 1,2,3 Butler J, 1 LaFleur J, 1,2 Kamauu AWC, 4 Schuerch M, 5 Foskett N, 5 Nelson RE. 1,3

  1. VA Salt Lake City Health Care System, Salt Lake City, UT
  2. University of Utah College of Pharmacy, Salt Lake City, UT
  3. University of Utah School of Medicine, Salt Lake City, UT
  4. Anolinx LLC, Salt Lake City, Utah
  5. F. Hoffman-La Roche, Basel, Switzerland

Presented: “Poster Session C: Burden of Disease/Epidemiology of Illness” on Wednesday, August 28, 2013. The publication number will be 807

Multiple Sclerosis Subtypes and Infections Resulting in a Hospitalization in the Veterans Health Administration.
Nelson RE, 1,2 Xie Y, 1,2 DuVall SL, 1,2,3 Butler J, 1 Kamauu AWC, 4 Schuerch M, 5 Foskett N, 6 LaFleur J. 1,3

  1. Salt Lake City Veterans Affairs Health Care System
  2. University of Utah School of Medicine, Salt Lake City, UT
  3. University of Utah College of Pharmacy, Salt Lake City, UT
  4. Anolinx, LLC, Salt Lake City, UT
  5. F. Hoffman-La Roche, Basel, Switzerland
  6. F. Hoffman-La Roche, Welwyn Garden City, UK

Presented: Poster Session B: SIG Database” on Tuesday, August 27, 2013. The publication number will be 593

Potential for Early Pharmacoepidemiologic Studies and Monitoring Intake of a Biologic Treatment Using an Electronic Health Records Database Prior to Assigned J-Code.
Aaron WC Kamauu, MD MS MPH, 1 Stephen Agbor, 1 Emily Dastrup, MS, 1 Scott L DuVall, PhD, 2, 3 Debra Maldonato, MS, 4 and Pavel Napalkov, MD MPH. 5

  1. Anolinx LLC, Salt Lake City, UT, United States, 84101
  2. VA Salt Lake City Health Care System, Salt Lake City, UT, United States
  3. University of Utah School of Medicine, Salt Lake City, UT, United States
  4. F Hoffman La Roche, Basel, Switzerland
  5. Genentech A Member of the Roche Group, South San Francisco, CA, United States

Presented: “Poster Session B: SIG Database” on Tuesday, August 27, 2013. The publication number will be 590

Characterization of Patients with ANCA-Associated Vasculitis by Subtype in the Veterans Affairs Database.
Scott L DuVall, PhD, 1, 2, 3 Aaron WC Kamauu, MD MS MPH, 4 Stephen OT Agbor, 4 Tmirah Haselkorn, PhD, 5 Pavel Napalkov, MD MPH, 5 Iain D Tatt, PhD, 5 and Curry L Koening, MD MS. 1, 2, 3

  1. VA Salt Lake City Health Care System, Salt Lake City, Utah, United States
  2. University of Utah College of Pharmacy, Salt Lake City, UT, United States
  3. University of Utah School of Medicine, Salt Lake City, UT, United States
  4. Anolinx LLC, Salt Lake City, UT, United States
  5. Genentech Inc, a member of the Roche Group, South San Francisco, CA, United States

Anolinx Projects:
Abstract #806
Presented: “Poster Session B: Methods” on Tuesday, August 27, 2013. The publication number will be 452

Conformity Between Protocol Eligibility Criteria For Electronic Patient Identification: A Comparison of Clinical Trials.
Allise G Kamauu, MS, 1 Stephen OT Agbor, 1 and Aaron WC Kamauu, MD MS MPH. 1

  1. Anolinx LLC, Salt Lake City, UT, United States, 84101

Abstract #941
Presented: “Poster Session B: SIG Database” on Tuesday, August 27, 2013. The publication number will be 594

Utilization of New Diagnosis Codes for Basal Cell Carcinoma in 2 Large Nationwide EHR Databases.
Aaron WC Kamauu, MD MS MPH, 1 Emily Dastrup, MS, 1 Yeun Mi Yim, MPH, 2 and Scott L DuVall, PhD. 3, 4

  1. Anolinx, Salt Lake City, UT, United States, 84101
  2. Genentech Inc.,, South San Francisco, CA, United States
  3. VA Salt Lake City Health Care System, Salt Lake City, UT, United States
  4. University of Utah School of Medicine, Salt Lake City, UT, United States

Abstract #809
Presented: “Poster Session B: SIG Database” on Tuesday, August 27, 2013. The publication number will be 578

Standard Method for Assessment of Electronic Health Record (EHR)D ata Sources for Pharmacoepidemiology.
Stephen OT Agbor, 1 Allise G Kamauu, MS, 1 and Aaron WC Kamauu, MD MS MPH. 1

  1. Anolinx LLC, Salt Lake City, Utah, United States


AnolinxTM is a data-driven clinical research and clinical trials recruitment company that utilizes electronic health records and advanced analytics to improve pharmacoepidemiology studies and clinical trials recruitment.

###

The comments are closed.

Categories